<DOC>
	<DOCNO>NCT02532439</DOCNO>
	<brief_summary>Bone fracture occurrence associate increase morbidity mortality . Some factor fracture occurrence highlight . For example , diseases therapy know increased risk bone fracture patient . Accordingly , important clinician identify patient risk bone fracture . Right , various tool available clinician : - clinical exam , - bone mineral density assess Dual Energy X-ray Absorptiometry ( DEXA ) , - algorithm base interrogation , clinical exam bone mineral density . However , prediction bone fracture risk need improve since 50 % bone fracture predict . DEXA provide information fracture risk estimation , unable distinguish cortical part trabecular part . It also fail quantify microstructural property influence bone strength . Bone microarchitecture , include cortical compartment assess vivo HR-pQCT . This technique allow access several parameter : one hand volumetric bone mineral density whole area measure well cortical trabecular region , hand , thickness cortical porosity number trabecular , orientation distribution . Thus , HR-pQCT allow realize virtual bone biopsy provide information cortical trabecular bone microarchitecture . This noninvasive way assess cortical trabecular bone microarchitecture .</brief_summary>
	<brief_title>Bone Microarchitectural Database Constitution From HR-pQCT Device Clinical Situation Potentially Associated With Bone Loss</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>1 . For patient : 1.1.Women Men take charge SaintEtienne ' Hospital one follow pathology : 1.1a : Osteoporosis define : history fracture bone fragility document 1.1b : Bone Fragility : Patient indication bone densitometry without fracture history 1.1c Articular inflammatory disease : Rheumatoid Arthritis , Spondyloarthritis 1.1d Endocrine disease : Primary Hyperparathyroidism , Constitutional Thinness , Anorexia nervosa 1.2. write consent 2 . For control : 2.1 . Episode acute back pain radicular pain ( last less month ) take corticosteroid less 1 month 2.2. write consent drug induce bone loss : 1.1.Antiaromasine GnRH agonist least 6 month , 1.2 . Corticosteroid therapy 1.3 . Antiepileptic carbamazepine , phenobarbital , phenytoin , primidone , valproic acid least 6 month ) 2. fracture due bone fragility 3. drug bone effect ( bisphosphonate , teriparatide , strontium ranelate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>fracture osteoporosis</keyword>
	<keyword>bone microarchitecture</keyword>
	<keyword>Inflammatory joint disease</keyword>
	<keyword>Bone fragility</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Spondyloarthritis</keyword>
	<keyword>Primary Hyperparathyroidism</keyword>
	<keyword>constitutional thinness</keyword>
	<keyword>anorexia nervosa</keyword>
</DOC>